- $121.93bn
- $140.83bn
- £32.67bn
- 98
- 63
- 99
- 99
REG - GSK PLC - Overall survival data presented for Blenrep
AnnouncementREG - GSK PLC - Blenrep combination China filing acceptance
AnnouncementREG - GSK PLC - Nucala COPD submission accepted by US FDA
AnnouncementREG - GSK PLC - Zhifei China collaboration revised and extended
AnnouncementREG - Allianz Global Invs - Top 10 Holdings
AnnouncementREG - GSK PLC - Director/PDMR Shareholding
AnnouncementREG - GSK PLC - Total Voting Rights
AnnouncementREG - GSK PLC - GSK liquid meningitis vaccine authorised in EU
AnnouncementREG - GSK PLC - Blenrep combinations accepted for US FDA review
AnnouncementREG - GSK PLC - Japan approves first RSV vaccine for adults 50-59
AnnouncementREG - GSK PLC - Director/PDMR Shareholding
AnnouncementREG - Stock Exch Notice - Admission to ISM - 19/11/2024
AnnouncementREG - GSK PLC - GLISTEN Trial of Linerixibat Meets Endpoint
AnnouncementREG - GSK PLC - GSK announces overall survival results for Blenrep
AnnouncementREG - GSK PLC - Block listing Interim Review
AnnouncementREG - GSK PLC - Director/PDMR Shareholding
AnnouncementREG - GSK PLC - GSK publishes provisional 2025 dividend dates
AnnouncementREG - Allianz Global Invs - Top 10 Holdings
AnnouncementREG - GSK PLC - Total Voting Rights
Announcement